Press Releases
- 150+ Partners Across Every Layer of AI Ecosystem Embedding NIM Inference Microservices to Speed Enterprise AI Application Deployments From Weeks to Minutes
- NVIDIA Developer Program Members Gain Free Access to NIM for Research, Development and Testing
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s 28 million developers can now download NVIDIA NIM™ — inference microservices that provide models as... (continue reading...)
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans, as well as new generative AI breakthroughs coming soon to the platform.
Companies in customer service, gaming and healthcare are the first to adopt ACE technologies to simplify creating, animating and operating lifelike digital humans across customer service,... (continue reading...)
57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung... (continue reading...)
- DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful benefit for patients in this setting
- Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2 positive metastatic breast cancer reinforce ENHERTU as standard of care in second-line setting and highlight potential in first-line setting
TOKYO & BASKING RIDGE,... (continue reading...)
DESTINY-Breast06 results show AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed medicine and ADC to demonstrate clinically meaningful benefit for patients in this setting
Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2-positive metastatic breast cancer reinforce ENHERTU as standard of care in 2nd-line setting and highlight potential in 1st-line setting
WILMINGTON, Del.--(BUSINESS WIRE)-- Detailed positive results... (continue reading...)
More Press Releases
View Older Stories-
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
RentFinder.ai Sets New Standards in Rental Estimates, Achieves 250% Surge in Usage
-
Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
-
June Joy at Juicy Stakes Casino
-
Accelerate Your Establishment Forward By Implementing These Simple Corporate Hacks
-
Exploring The Main Aspects To Consider When Eradicating Pesky Pests From Your Home
-
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
Top 10 Compelling Reasons Why Your Kids Should Have Regular School Physicals
-
Odyssey Capital participated in the Washington D.C. Blockchain Summit, proposing the establishment of a Global Special Assets Alliance Fund initiative.
-
Are Ruby Gemstones Worth Investing In?
-
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
-
Capsucup: Where Quality and Sustainability Meet in Italian Espresso
-
Leading Contractor Marketing Agency Webrunner Media Broadens Service Portfolio
-
Xfive Recognized as a Clutch Global Leader for Spring 2024
-
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
-
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
-
Eyes Defined Introduces 3D Images to Revolutionize Eyelid Surgery Planning
-
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
-
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
-
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaka' at the UEFA Champions League Final 2024
-
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaká at the UEFA Champions League Final 2024
-
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever
-
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
-
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
-
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
-
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a La
-
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
-
Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
-
BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
-
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
-
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
-
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy
-
Sun, Sand, and Smooth Skin: Grab Ulike Air 10 for a Summer Beach Adventure
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Robotbulls - The Future of Cryptocurrency Trading: Integrating AI and Blockchain Data
-
What Custom Stickers Are Best for Glass?
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd
-
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
-
All-in-One Job Shop Software for Fabrication Shops by Steelhead Technologies
-
Taseko Announces that Operations at its Gibraltar Mine have been Suspended